Disease Domain | Count |
---|---|
Neoplasms | 2 |
Immune System Diseases | 2 |
Hemic and Lymphatic Diseases | 1 |
Endocrinology and Metabolic Disease | 1 |
Top 5 Drug Type | Count |
---|---|
Natural Killer Cell Therapies | 1 |
Immune cell therapy | 1 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Jun 2025 |
Sponsor / Collaborator |
Start Date01 Mar 2025 |
Sponsor / Collaborator |
Start Date01 Mar 2025 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
NK-042 | Lupus Nephritis More | Phase 1 |
NK-010 | Lupus Nephritis More | Phase 1 |